Beyond bacterial defences: the role of lysozyme in cancer
Clinical and Translational Medicine · 2026-02 · 16 (2)
DOI: 10.1002/ctm2.70575 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 01.02.2026. Verfasst von Lei Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Life Science, Beijing University of Technology, Beijing, China. Hauptthemen laut MEDLINE: Neoplasms, Muramidase. Die Arbeit nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
Lysozyme (LYZ) is a naturally occurring antimicrobial protein first discovered in the 1920s. As a key component of innate immunity, its antimicrobial effects and immunomodulatory functions in bacterial defence have been extensively characterized. However, emerging evidence since the 1950s has revealed its complex involvement in tumour progression, with conflicting reports of both tumour‐suppressive and tumour‐promoting effects across different cancer types. A critical knowledge gap remains in understanding the mechanistic basis for this duality, exacerbated by reliance on single‐omics approaches and small cohorts in previous studies. This review focuses on mammalian C‐type LYZ (referred to as LYZ hereafter unless specified) and integrates multi‐omics data (transcriptomics and proteomics) with clinical and mechanistic research to systematically dissect its dual roles in cancer. By analysing cross‐cancer heterogeneity through multi‐omics perspectives, we emphasize its dual promise as both a prognostic biomarker and an actionable therapeutic target, aiming to provide new insights for precision oncology. Key points LYZ is a multi‐functional secreted factor that encompasses both antibacterial and immunomodulatory functions. Emerging evidence highlights its complex role in tumour progression by directly influencing tumour cells and modulating the immune microenvironment. LYZ is a promising potential biomarker and therapeutic target in some cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Chemistry and Life Science, Beijing University of Technology, Beijing, China.
- State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Research Unit of Proteomics-Driven Cancer Precision Medicine (Chinese Academy of Medical Scie…
- Department of Laboratory Medicine, Peking University Third Hospital, Beijing, China.
- Core Unit of National Clinical Research Center for Laboratory Medicine, Peking University Third Hospital, Beijing, China.
Förderung
- National Key Research and Development Program of China
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
- National Natural Science Foundation of China
- Peking University Third Hospital Clinical Key Project
Zitieren
APA
Wang, L., Dong, Q., He, F., Gu, Z., & Sun, A. (2026). Beyond bacterial defences: the role of lysozyme in cancer. Clinical and Translational Medicine, 16(2). https://doi.org/10.1002/ctm2.70575
Vancouver
Wang L, Dong Q, He F, Gu Z, Sun A. Beyond bacterial defences: the role of lysozyme in cancer. Clinical and Translational Medicine. 2026;16(2). doi:10.1002/ctm2.70575
BibTeX
@article{Wang2026,
author = {Wang, Lei and Dong, Qian and He, Fuchu and Gu, Zhiwen and Sun, Aihua},
title = {Beyond bacterial defences: the role of lysozyme in cancer},
journal = {Clinical and Translational Medicine},
year = {2026},
volume = {16},
number = {2},
doi = {10.1002/ctm2.70575}
}
EUVIMED